Citation

Huie JR, Diaz-Arrastia R, Yue JK, Sorani M, Puccio A, Okonkwo DO, Manley GT, Ferguson AR. J. Neurotrauma 2019; 36(1): 100-110.

Affiliation

UCSF, Brain and Spinal Injury Center, Dept Neurosurgery , 1001 Potrero Ave , 1001 Potrero Ave , San Francisco, California, United States , 94110 ; adam.ferguson@ucsf.edu.

Copyright

(Copyright © 2019, Mary Ann Liebert Publishers)

DOI

10.1089/neu.2017.5449

PMID

30084741

Abstract

The complex and heterogeneous nature of traumatic brain injury (TBI) has rendered the identification of diagnostic and prognostic biomarkers elusive. A single acute biomarker may not be sufficient to categorize injury severity and/or predict outcome. Using multivariate dimension reduction analyses, we tested the sensitivity and specificity of a multianalyte panel of proteins as an ensemble biomarker for TBI. Serum was collected within 24 hours of injury in a cohort of 130 patients enrolled in the multicenter prospective Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot (TRACK-TBI Pilot) study and run on an array that measured 72 proteins. Using unsupervised principal components analysis, we first identified the subset of protein changes accounting for the most variance across patients. This yielded a group of 21 proteins that reflected an inverse relationship between inflammatory cytokines and regulators of anti-inflammation, and generated an individual inflammatory profile score for each patient. We then tested the association between these scores and computed tomography (CT) findings at hospital admission, as well as their prognostic association with functional recovery at 3 and 6 months (Glasgow Outcome Scale-Extended), and cognitive recovery at 6 months (California Verbal Learning Test, Second Edition) after injury. Inflammatory signatures were significantly increased in patients with positive CT findings, as well as in those that showed poor or incomplete recovery. Inflammation biomarker scores also showed significant sensitivity and specificity as a discriminator of these outcome measures (all AUCs > 0.62). This proof-of-concept for the feasibility of multivariate biomarker identification demonstrates the prognostic validity of using a proteomic panel as a potential biomarker for TBI.

Language: en

Keywords

BIOMARKERS; PROTEOMICS; TRAUMATIC BRAIN INJURY